NCT03887442终止2 期
Phase II, Randomized Clinical Trial to Assess the Efficacy of Paclitaxel vs Paclitaxel + Cetuximab in Subjects With Recurrent and/or Metastatic Squamous Head & Neck Carcinoma After Failure of a 1º Line Chemotherapy EXTREME Type Treatment
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 17
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed the informed consent
- •Age ≥ 18 and < 75 y
- •ECOG (Eastern Cooperative Oncology Group)performance status: 0-1
- •Life expectancy of at least 12 weeks
- •Histological or cytological confirmation of head & neck squamous cell carcinoma with localization in larynx, oropharynx, oral cavity or hypopharynx.
- •Having received at least 2 cycles of EXTREME-type chemotherapy (cisplatin or carboplatin + fluoropyrimidines + cetuximab) and being in maintenance phase with cetuximab because of having reached CR (Complete response), PR (Partial response) or SD (Stable disease) to said treatment
- •At least one measureable lesion by CT scan or MRI
- •Adequate bone marrow, liver and kidney function, according to:
- •Hb (Hemoglobin) ≥ 9.0 g/dl
- •Platelets 100,000/mm3
- •ANC (Absolute Neutrophil Count) ≥ 1,500/mm3
- •Total bilirubin ≤ 2 times the UNL
- •SGPT/ALT and SGOT/AST ≤ 3 x UNL (Upper normal limit)
- •Alkaline phosphatase ≤ 2.5 x UNL
- •Serum creatinine ≤ 1.5 times the ULN or creatinine clearance > 50 ml/min
- •Adequate nutritional status: weight loss < 20% in relationship to usual weight or albumin ≥ 35 g/l, in the last 12 w
- •Seric calcium adjusted to albumine lower or equal to 1,25 UNL.
- •Toxicity, due to previous treatment received, resolved to grade 1, before enrolment in the study
- •Women of childbearing potential should have a (-)ve pregnancy test in serum or urine,7 d before randomization. Postmenopausal women should have remained amenorrheic for at least 12 m. Furthermore, all men as well as women who participate in this study should use effective contraceptive methods beginning with the signing of the informed consent form and up to at least 6 m after the completion of the study or of the last dose, whichever occurs first
排除标准
- •Treatment for recurrent and/or metastatic disease other than the EXTREME- type first line (cisplatin or carboplatin + fluoropyrimidines + cetuximab)
- •Non-measurable lesion as only evidence of disease
- •Nasopharyngeal carcinoma
- •Clinical or radiographic evidence of brain metastases
- •Having history of or presenting clinically significant cardiovascular disease, such as, but not limited to, congestive heart failure, ≥ grade II of the NYHA, severe cardiac arrhythmias that require medication, or ≥ grade II peripheral vascular disease. Furthermore, those patients who have suffered myocardial infarction or unstable angina in the year prior to the onset of the study treatment or a recent onset angina in the last 3 m will also be excluded
- •History of or current presence of grade >1 peripheral neuropathy
- •History of active neurological disease
- •History of uncontrolled convulsive episode
- •Current ≥ 2 grade infection
- •Known infection by HIV or chronic infection by HBV or HBC or presence of uncontrolled and severe intercurrent infections or other severe and uncontrolled concomitant diseases
- •History of uncontrolled diabetes, uncontrolled HBP or hepatic condition.
- •History of pulmonary fibrosis, acute pulmonary damage or interstitial pneumonia
- •Any antineoplastic treatment within the 4 w prior to the randomization period
- •History of another neoplastic disease during the last 5 y, with the exception of cured "in situ" basal cell ca.skin carcinoma, "in situ" ca.bladder, "in situ" ca.cervix and "in situ" ca.prostate
- •Known allergy or suspicion of allergy or hypersensitivity to any component of cetuximab or paclitaxel
- •Previous treatment with monoclonal antibodies or other signal transduction inhibitors or EGFR-targeted treatment (Except for previous treatment with cetuximab)
- •Known drug abuse (exception Alcoholism)
- •Any important and uncontrolled medical, psychological, psychiatric, geographic or social problem that may interfere in the participation of the subject in the study and that does not allow for adequate follow-up and compliance with the protocol and evaluation of the study results
- •Women who are pregnant or in breast-feeding period
- •Use of any investigational new drug within the 4 w prior to randomization
研究组 & 干预措施
Paclitaxel
Active Comparator
Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
干预措施: Paclitaxel (Drug)
Cetuximab + Paclitaxel
Experimental
Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
干预措施: Cetuximab + Paclitaxel (Drug)
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The primary endopoint was not analyzed.
The primary endpoint was to select the most effective treatment arm based on the progression-free survival (PFS) reached in each treatment arm. This was defined as the time elapsed from inclusion in the study until the date when disease progression or death (for any cause) was documented.
次要结局
- Treatment Compliance(3 years)
- Percentage of Objective Response(Through study completion. The study was prematurely closed at 19 months due to lack of accrual. Neither the primary nor the secondary endopoints were analyzed.)
- Overall Survival(Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The secondary endopoint was not analyzed.)
- Participants With Adverse Events(The duration of the study (Nineteen months) and until the last patient included completed one year of follow up / died or was lost to FU. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.)
研究者
相似试验
招募中
2 期
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck CancerLocally Advanced Head and Neck CancerNCT03532737Kuwait Cancer Control Center50
已完成
2 期
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)NCT04282109Grupo Español de Tratamiento de Tumores de Cabeza y Cuello141
已完成
2 期
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT02823574Bristol-Myers Squibb425
已完成
1 期
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck CancerRecurrent Head and Neck CancerNCT02422979Rakuten Medical, Inc.40
招募中
不适用
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCCSquamous Cell Carcinoma of Head and NeckNCT04688528Universitaire Ziekenhuizen KU Leuven147